These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24214141)

  • 1. The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration.
    Kim HS; Cho DY; Park BM; Bae SK; Yoon YJ; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
    J Clin Pharmacol; 2014 Aug; 54(8):850-7. PubMed ID: 24214141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.
    Kim HS; Lim Y; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
    Br J Clin Pharmacol; 2016 Feb; 81(2):301-12. PubMed ID: 26426352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects.
    Song BL; Wan M; Tang D; Sun C; Zhu YB; Linda N; Fan HW; Zou JJ
    Clin Ther; 2018 Jul; 40(7):1170-1178. PubMed ID: 30017169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.
    Horenstein RB; Madabushi R; Zineh I; Yerges-Armstrong LM; Peer CJ; Schuck RN; Figg WD; Shuldiner AR; Pacanowski MA
    J Clin Pharmacol; 2014 Aug; 54(8):865-73. PubMed ID: 24710841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-antiplatelet effect of clopidogrel: improving endothelial function in Chinese healthy subjects with different CYP2C19 genotype.
    Zhang YZ; Chen BL; Zhang W; Cao X
    Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):22-6. PubMed ID: 25311974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
    Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ
    J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
    Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Oszkinis G; Główka F
    J Clin Pharmacol; 2014 Aug; 54(8):874-80. PubMed ID: 24782221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
    Kobayashi M; Kajiwara M; Hasegawa S
    J Atheroscler Thromb; 2015; 22(11):1186-96. PubMed ID: 26063503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.
    Sridharan K; Kataria R; Tolani D; Bendkhale S; Gogtay NJ; Thatte UM
    Indian J Pharmacol; 2016; 48(4):350-354. PubMed ID: 27756942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.
    Hokimoto S; Chitose T; Mizobe M; Akasaka T; Arima Y; Kaikita K; Iwashita S; Morita K; Miyazaki H; Oniki K; Matsui K; Nakagawa K; Ogawa H
    Eur J Clin Pharmacol; 2014 Jun; 70(6):667-73. PubMed ID: 24763934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.
    Kim KA; Park PW; Hong SJ; Park JY
    Clin Pharmacol Ther; 2008 Aug; 84(2):236-42. PubMed ID: 18323861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
    Kelly RP; Close SL; Farid NA; Winters KJ; Shen L; Natanegara F; Jakubowski JA; Ho M; Walker JR; Small DS
    Br J Clin Pharmacol; 2012 Jan; 73(1):93-105. PubMed ID: 21689142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.
    Furuta T; Iwaki T; Umemura K
    Br J Clin Pharmacol; 2010 Sep; 70(3):383-92. PubMed ID: 20716239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers.
    Wu J; Jia LT; Shao LM; Chen JM; Zhong DD; Xu S; Cai JT
    Eur J Clin Pharmacol; 2013 Feb; 69(2):179-87. PubMed ID: 22706585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between the CYP2C19 phenotype status and the results of three different platelet function tests in cardiovascular disease patients receiving antiplatelet therapy: an emphasis on newly introduced platelet function analyzer-200 P2Y test.
    Li S; Choi JL; Guo LZ; Goh RY; Kim BR; Woo KS; Kim MH; Han JY
    Ann Lab Med; 2016 Jan; 36(1):42-8. PubMed ID: 26522758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.
    Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C
    Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
    Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K
    Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP2C19 loss-of-function variants on the metabolism of clopidogrel in patients from north-western China.
    Lin R; Zhang L; Zhang P; Zhou L; Liu T; Li Y; Zhang W; Wang W; Zhang J
    J Clin Pharm Ther; 2015 Jun; 40(3):308-14. PubMed ID: 25810245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.